SaMD Certification and Regulatory Support

What Is SaMD Certification and Why It Matters

Software as a Medical Device (SaMD) refers to software that performs medical functions — such as diagnosis, monitoring, or clinical decision support — without being part of a physical medical device. SaMD certification is a critical requirement for entering regulated markets like the EU, US, UK, and Australia. 

Certification ensures compliance with software as medical device regulations (FDA SaMD guidance, EU MDR, MHRA, TGA, IMDRF standards) and proves the product is safe, effective, and reliable. This builds trust among physicians, patients, and payers while unlocking opportunities such as reimbursement and government adoption. 

Failure to obtain proper SaMD registration brings serious risks: market bans, financial penalties, product recalls, and reputational damage. For innovative AI- or ML-based solutions, regulators pay special attention to algorithm safety and transparency, making proper certification even more crucial. 

Country-Specific Requirements and Market Overview

Certification requirements vary depending on the regulatory authority: 

• United States (FDA):
  SaMD is classified by risk level. Depending on classification, pathways include Premarket Notification (510(k)), De Novo, or Premarket Approval (PMA) for high-risk devices. 

• European Union (EU MDR):
  SaMD falls under the Medical Device Regulation (MDR). Classification is based on Annex VIII rules, requiring engagement with a Notified Body and CE marking. 

• United Kingdom (MHRA, UKCA):
  Post-Brexit, the UK applies its own framework. Certification requires review by Approved Bodies and UKCA labeling. 

• Australia (TGA):
  Based on IMDRF guidance, all SaMD must be listed in the Australian Register of Therapeutic Goods (ARTG). 

The global SaMD market is expanding rapidly, driven by rising prevalence of chronic diseases and adoption of digital health solutions. Some governments actively support innovation through grants, tax incentives, or fast-track programs for digital health products, making market entry more attractive. 

Preparing a Market-Focused Regulatory Submission

A successful regulatory pathway begins with a market-specific strategy. Each submission dossier typically includes: 

• Technical Documentation – software architecture, validation & verification reports, cybersecurity measures. 
• Quality System Documentation – evidence of compliance with ISO 13485 and IEC 62304 standards. 
• Clinical Evaluation Report (CER) – literature review and/or clinical evidence demonstrating safety and effectiveness. 
• Labeling and Instructions for Use (IFU) – properly localized and adapted to target market expectations. 

While the overall structure is similar worldwide, local regulatory expectations differ. For example, the FDA emphasizes clear algorithm justification, while EU regulators focus strongly on risk management (ISO 14971) and lifecycle documentation. 

When Is a Clinical Study Required?

Not every SaMD requires a clinical study. However, clinical data is mandatory when: 

• introducing novel algorithms (AI/ML) without proven equivalence, 
• developing high-risk SaMD (Class IIb–III in EU, Class III in US), 
• literature data alone is insufficient to demonstrate performance and safety. 

For clinical trial approval, sponsors must prepare a documentation package including: study protocol, informed consent forms, ethics committee approval, and a risk management file. After completion, clinical data is integrated into the regulatory submission to secure certification. 

Certification Process and Timelines

The SaMD certification process typically includes: 

1. Risk classification based on IMDRF principles and local regulations. 
2. Preparation of technical and quality documentation. 
3. Submission to the regulatory authority (FDA, Notified Body, MHRA, TGA). 
4. Interactive review – responses to authority questions and provision of additional data. 
5. Final approval and certification – CE mark, FDA clearance, UKCA, or ARTG entry. 

The timeline varies by region and product complexity but usually ranges from 6 to 12 months. For AI-driven SaMD, additional reviews on safety, transparency, and explainability may extend the process.